Company recently received IND approval from FDA to begin limited clinical trials with the antiviral agent in patients with AIDS. American patients who have been receiving HPA-23 on a regular basis in France under circumstances not under control of Rhone-Poulenc will be allowed to be treated under the care of independent investigators at a limited number of U.S. medical centers.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.
“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry.